Large Put Spread Targets Axsome Therapeutics Decline Ahead of Clinical Trial Results

A significant and highly directional options trade in Axsome Therapeutics (NASDAQ: AXSM) suggests at least one large market participant is positioning for a near-term drop in the company's stock price. On Tuesday, put options, which profit from a fall in the share price, accounted for 92.7% of the total options volume, a stark imbalance indicating bearish sentiment.

Anatomy of the Trade

The most prominent activity was a large ratio put spread structured to profit from a decline toward the $170 level by mid-October. According to market data, the trade involved buying puts at the $185 and $170 strike prices with an October 16, 2026, expiration date.

A key detail highlighting the conviction behind the trade is the change in open interest. The open interest on the $170 strike puts was just a single contract before Tuesday's session but swelled by 1,200 contracts following the trade. This indicates the position is entirely new money being put to work, not an adjustment of a pre-existing position.

Market Signals Point to Caution

Broader options market metrics support the bearish interpretation of this trade. Three-month implied volatility for Axsome shares rose, signaling that the market is pricing in a higher probability of a large price swing in the coming weeks. The stock was down more than 5% during Tuesday's trading.

Ad

Furthermore, the volatility skew, which measures the premium of put options relative to call options, also increased. A rising skew indicates that demand for downside protection is growing, a classic signal of institutional concern or bearish positioning ahead of a potential catalyst.

Context: A Key Catalyst Looms

The timing of the options trade aligns with a critical upcoming event for the biopharmaceutical company. Axsome is expected to release top-line data from its ENGAGE Phase III trial of solriamfetol for binge eating disorder in the fourth quarter of 2026. Such clinical trial readouts are often binary events that can cause sharp, sudden moves in a company's stock price.

While the options activity is notably bearish, Axsome has supporters. The company's drug AUVELITY generates significant revenue, and analysts at firms including Jefferies and TD Cowen hold price targets well above the current stock price, at $380 and $300 respectively. It is possible, though less likely given the trade's structure, that the position is a sophisticated hedge against a large existing long stock position.